Meet Our Editorial Board Member

Andrius Baskys

Graduate College of Biomedical Sciences
Western University of Health Sciences
Pomona, California
USA

Dr. Andrius Baskys is a practicing psychiatrist, neuroscientist, inventor and educator. He has over 30 years of experience in mental health care and research focusing on memory disorders, their diagnosis and treatment. He completed his psychiatry residency at the University of Toronto, Canada, clinical fellowship at McMaster University, Hamilton and post-doctoral training at the University of California San Francisco. During his career, he has taught and conducted research as a faculty member at the University of Toronto, University of California Irvine, UCLA as well as, more recently, holding a visiting Professorship at the Fourth Military Medical University (FMMU) in Xi'an, China. Dr. Baskys published over 200 papers, presentations and reports and two textbooks on psychopharmacology. His most important scientific contributions are in the area of metabotropic glutamate receptor physiology and pharmacology. His research interests are pharmacogenomics, vascular dementia and development of AI-powered tools for bringing pharmacogenomic information to clinical practice.

Andrius Baskys

Dr. Baskys serves on the Editorial Boards of Current Neuropharmacology and Clinical Handbook of Psychotropic Drugs. He is a member of the International Expert Panel for the Singapore Ministry of Health and is the Vice President of the World Association of Genomic Medicine headquartered in La Coruña, Spain.

SELECTED PUBLICATIONS

- [1] Baskys, A. Pharmacogenomic Information for Common Psychotropic Drugs. *Clinical Handbook of Psychotropic drugs*, 22nd ed; Procyshyn, R.M.; Bezchlibnyk-Butler, K.Z.; Jeffries, J.J., Eds.; Hogrefe, **2017**.
- [2] Cheung, Y.; Summerour, R.B.; Cui, X.; Baskys, A. Testing for CYP polymorphisms is associated with a reduction in the frequency of changes in psychotropic prescriptions made by community psychiatrists. *J. Genom. Med. Pharmacog.*, **2016**, *1*, 1-5.
- [3] Baskys, A. Integration of genomic information in development of pharmacological vascular dementia prevention and treatment strategies. *J. Alzheimers Dis.*, **2014**, *42*(0)(Suppl. 3), S267-S276. [PMID: 25024308]
- [4] Baskys, A.; Cheng, J-X. Pharmacological prevention and treatment of vascular dementia: approaches and perspectives. *Exp. Gerontol.*, **2012**, *47*(11), 887-891. [http://dx.doi.org/10.1016/j.exger.2012.07.002] [PMID: 22796225]
- [5] Koontz, J.; Baskys, A. Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study. *Am. J. Alzheimers Dis. Other Demen.*, **2005**, *20*(5), 295-302. [http://dx.doi.org/10.1177/153331750502000502] [PMID: 16273995]
- [6] Baskys, A.; Bayazitov, I.; Fang, L.; Blaabjerg, M.; Poulsen, F.R.; Zimmer, J. Group I metabotropic glutamate receptors reduce excitotoxic injury and may facilitate neurogenesis. *Neuropharmacology*, **2005**, *49*(Suppl. 1), 146-156. [http://dx.doi.org/10.1016/j.neuropharm.2005.04.029] [PMID: 16023152]
- [7] Baskys, A. Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. *J. Clin. Psychiatry*, **2004**, *65*(Suppl. 11), 16-22. [PMID: 15264967]
- [8] Blaabjerg, M.; Baskys, A.; Zimmer, J.; Vawter, M.P. Changes in hippocampal gene expression after neuroprotective activation of group I metabotropic glutamate receptors. *Brain Res. Mol. Brain Res.*, **2003**, *117*(2), 196-205. [http://dx.doi.org/10.1016/S0169-328X(03)00321-8] [PMID: 14559154]
- [9] Baskys, A.; Malenka, R.C. Metabotropic glutamate receptor agonists depress synaptic transmission in area CA1 of rat hippocampus. *J. Physiol.*, **1991**, *444*, 687-701. [http://dx.doi.org/10.1113/jphysiol.1991.sp018901] [PMID: 1668353]